Welcome to our dedicated page for LMNGF news (Ticker: LMNGF), a resource for investors and traders seeking the latest updates and insights on LMNGF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LMNGF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LMNGF's position in the market.
BioVaxys Technology Corp. (OTC: BVAXF) announced it has filed an intent-to-use trademark application for CoviDTH®, a T-cell immune response diagnostic for SARS-CoV-2. This move aims to secure a distinctive mark as the product approaches the market. Additionally, BioVaxys broadened its intellectual property by filing an international patent application via the Patent Cooperation Treaty for its bihaptenized tumor antigen vaccine platform, covering various cancers, including cervical and ovarian cancer. The company continues to strengthen its vaccine development initiatives.
BioVaxys Technology Corp. announced the assignment of a new US OTC trading symbol, BVAXF, effective April 21, 2021, replacing the previous symbol LMNGF. The company has applied for an OTCQB listing, which is expected to be approved soon. BioVaxys specializes in developing haptenized antigen vaccines targeting both viral and oncology applications. The firm is advancing its SARS-CoV-2 vaccine technology and planning a clinical trial focusing on ovarian cancer. They hold two US patents and have additional patent applications pending.
BioVaxys Technology Corp. (OTC: LMNGF) has announced its sponsorship of World Ovarian Cancer Day on May 8, aiming to raise awareness about ovarian cancer. The initiative, supported by over 170 organizations, highlights the significant unmet needs in ovarian cancer treatments, where 300,000 women are diagnosed annually. BioVaxys is advancing its ovarian cancer vaccine, BVX-0918A, in collaboration with ProCare Health, which plans to file for clinical trials in the EU. The global ovarian cancer drug market is forecasted to grow from US$1.2B in 2017 to US$4.6B by 2026.
BioVaxys Technology Corp. announces its clinical study results on Papilocare® for HPV treatment, highlighting a 88% normalization rate of cervical lesions and a 63% clearance rate of high-risk HPV. Conducted by ProCare Health Iberia, the study involved nine hospitals across Spain and was published in the Journal of Lower Genital Tract Disease. BioVaxys holds marketing rights in the U.S. for Papilocare®, further enhancing its portfolio in gynecological cancer and viral vaccine applications.
BioVaxys Technology Corp. (OTC: LMNGF) has filed a pre-IND meeting request with the FDA for Covid-T, a T-cell immune response diagnostic for SARS-CoV-2. This meeting allows the company to clarify clinical trial designs and manufacturing procedures. Anticipation surrounds a written FDA response expected later this month. The FDA previously indicated BioVaxys could file for a pre-EUA for Covid-T, though the company does not claim its product can eliminate or treat COVID-19 at this time. BioVaxys is focused on developing vaccines and diagnostics for viral and oncological applications.
BioVaxys Technology Corp. expands its intellectual property portfolio by filing an international patent application for its haptenized viral antigen vaccine platform, targeting emerging SARS-CoV-2 variants, including UK, South Africa, and Brazil lineages. The application has transitioned from a provisional to a PCT filing, allowing global patent protection across over 150 countries. Additionally, the company entered the National Phase for its ovarian cancer vaccine patent, pursuing protection in key markets like the US, EU, and China. CEO Kenneth Kovan emphasizes the importance of patent protection for future product development.
BioVaxys Technology Corp. (OTC: LMNGF) announced an agreement with Inotiv to conduct preclinical toxicology studies for its Covid-T™ immunodiagnostic. This test aims to assess T cell immunity against SARS-CoV-2 and the effectiveness of various vaccines. The study will evaluate the safety of purified SARS-CoV-2 s-protein, with results expected in early summer. Successful completion is vital for a pivotal human trial planned later this year, pending FDA approval. BioVaxys emphasizes that it is not claiming to treat SARS-CoV-2 at this time.
BioVaxys Technology Corp. announced a significant bioproduction agreement with WuXi Biologics to synthesize SARS-CoV-2 s-proteins for its COVID-19 vaccine candidate, BVX-0320, and its Covid-T™ immunodiagnostic program. The agreement aims to produce GLP-grade s-protein for preclinical studies and GMP-grade for clinical trials, enhancing protein purity and economic viability. BioVaxys plans to submit a pre-IND meeting request to the FDA for Covid-T next month, indicating progress in its vaccine and diagnostic development.
BioVaxys Technology Corp. (OTC: LMNGF) announced on March 1, 2021, its initiative to enhance its SARS-CoV-2 vaccine, BVX-0320, and the Covid-T diagnostic to combat emerging variants such as the UK, South African, and Brazilian strains. The company is exploring a multivalent vaccine that combines spike protein subunits from these variants. Preliminary studies indicate that the monovalent vaccine has shown a 96.4% spike protein-binding antibody response. However, BioVaxys warns that current analyses do not guarantee treatment efficacy against SARS-CoV-2 variants.
BioVaxys Technology Corp. (OTC: LMNGF) has appointed Dr. Kartik Chandran to its Scientific Advisory Board. Dr. Chandran, an expert in microbiology and immunology at Albert Einstein College of Medicine, will lend his expertise in developing vaccines for viral diseases. His experience includes research on coronaviruses and filoviruses. BioVaxys focuses on advancing its haptenized viral vaccine platform aimed at life-threatening viruses, including SARS-CoV-2, as it prepares for clinical trials. The company is also developing a diagnostic to evaluate T cell immune responses to COVID-19.
FAQ
What is the market cap of LMNGF (LMNGF)?
